Industry NewsImmunovia, Inc. receives CLIA approval to begin testing of patients for pancreatic cancer with IMMray PanCan-d test
Product NewsProteomic data derived from Immunovia’s IMMray™-platform allows differential diagnosis of difficult to distinguish autoimmune diseases
Industry NewsExcellent Results Across All Symptomatic Risk Groups from Immunovia IMMray™ PanCan-d Optimization Work
Industry NewsImmunovia Accelerates Pancreatic Cancer Study of New Onset Diabetics by Adding Denmark’s DD2 Diabetes Center for Strategic Research
